<DOC>
	<DOCNO>NCT02481583</DOCNO>
	<brief_summary>The aim study characterise pharmacokinetic property assess safety different formulation levosulpiride healthy Chinese volunteer .</brief_summary>
	<brief_title>Pharmacokinetic Study Levosulpiride</brief_title>
	<detailed_description>Levosulpiride administer 42 healthy male female ( 1:1 ) subject tablet ( orally ) injection ( intramuscularly intravenously ) formulation . Blood sample collect regular interval single multiple drug administration . The concentration levosulpiride plasma determine use validated high performance liquid chromatography-tandem mass spectrometry method . Non-compartmental analysis perform estimate pharmacokinetic parameter . The analysis variance use test linearity ass effect gender pharmacokinetic property study drug . Adverse effect monitor use investigator ' questionnaire subject ' spontaneous report , vital sign measurement , hematology , clinical chemistry , electrocardiogram .</detailed_description>
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Sulpiride</mesh_term>
	<criteria>body mass index between19 24 kg/m2 negative HIV hepatitis B clinical important finding health test thorax radiography ECG abnormalities normal blood pressure value heart rate drug treatment within 2 week start study participation another clinical study within previous 3 month alcoholism smoke pregnancy breastfeed hypocalcemia blood donation participation clinical trial within 3 month enrollment study sit blood pressure &lt; 80/50 mm Hg &gt; 140/100 mm Hg A ventricular rate &lt; 60 beats/min &gt; 100 beats/min rest</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>levosulpiride</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>adverse effect</keyword>
	<keyword>bioavailability</keyword>
</DOC>